Generics giants jostle over pain drug


The US Food and Drug Administration (FDA) has approved the first batch of generic competitors to Pfizer’s non-steroidal anti-inflammatory Celebrex (celecoxib). Teva received approval for its 50, 100, 200 and 400mg doses, and Mylan also had its 50mg dose approved. Actavis, which was also in the running, is yet to receive final approval for any of its celecoxib generics.

The agency has also granted Teva 180 days’ market exclusivity for all but the 50mg form, under US provisions designed to encourage generic competition. Both Mylan and Actavis have attempted to sue the FDA for this decision, which Mylan has called an ‘unprecedented error’ and Actavis described in a statement as ‘arbitrary, capricious and contrary to law’. The court denied Mylan’s injunction, but the company has signalled its intention to appeal that decision.

Mylan has also negotiated an agreement with Pfizer to launch its generic versions in December 2014, or earlier under certain conditions. All three companies now have such agreements in place.


Related Content

Generics triumph in anti-inflammatory patent battle

25 April 2014 Business

news image

Pfizer settles deals to allow copycat celecoxib

Generics giant Mylan offers $30 billion for Perrigo

13 April 2015 Business

news image

Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes

Most Read

Schott's glass

29 April 2015 Classic Kit

news image

Life through a lens

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

Science for life: a manual for better living

1 May 2015 Review

news image

Looking beyond the hype

An unfortunate oversight

27 April 2015 Critical Point

news image

The US Toxic Substances Control Act is in dire need of reform. That demands compromises, says Mark Peplow